The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA®</ ...

Aromatase inhibitors (AIs) have emerged as the standard therapy for postmenopausal patients with estrogen/progesterone receptor-positive breast cancer. As adjuvant therapy, treatment is typically ...

In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...

Key Takeaways Leflutrozole, an aromatase inhibitor, is being tested in a phase 2 trial for male infertility due to low testosterone levels. The trial will enroll 200 patients, assessing leflutrozole's ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...